

Unique technical features as demonstrated by recent data



#### Introduction

The Easyhaler performs consistently, irrespective of a patient's inhalation flow<sup>1,2</sup>

Patients receive a consistent fine particle dose with the Easyhaler<sup>1</sup>

Patients prefer the Easyhaler to other dry powder inhalers<sup>3,4</sup>


What are some of the unique technical features of the Easyhaler that may be behind these findings?

Malmberg LP, et al. J Aerosol Med Pulm Drug Deliv 2014;27:329-40; 2. Haikarainen J, et al. Pulm Ther 2017;3:125-38;
Giner J, et al. Arch Bronconeumol 2004;40:106-9; 4. Pirozynski M et al. Adv Ther 2017;34:2648-60



The Easyhaler is a high or medium-to-high resistance dry powder\* inhaler generating highly turbulent air flow within the inhaler, even with low patient inhalation flows PHARMA

During an inhalation, air enters the Easyhaler **around the actuator** and encounters **high or medium-to-high resistance,\*** due to the small size of the air vent



(2) High or medium-to-high resistance generates turbulent air flow to the dosing cup

(3) Turbulent air flow ensures de-aggregation of drug particles and accurate dose delivery, even with low patient inhalation flows

\*Easyhaler M (Monotherapy) is a high resistance inhaler and Easyhaler C (Combination) is a medium-to-high resistance inhaler 1. Chrystyn H. Clin Drug Invest 2006;26:175-83; 2. Malmberg LP, et al. J Aerosol Med Pulm Drug Deliv 2014;27:329-40


#### Why is turbulent air flow within an inhaler important?



It generates high air flow speed and force to the dosing cup (1)

It guarantees the emission of all powder from the dosing (2)


It ensures de-aggregation of drug particles from carrier molecules, the formation of fine particles and an optimal speed for lung deposition (3)



### The Easyhaler is a high or medium-to-high resistance inhaler\*




Inspiratory resistance of marketed dry powder inhalers<sup>1,2</sup>



\*Easyhaler M (Monotherapy) is a high resistance inhaler and Easyhaler C (Combination) is a medium-to-high resistance inhaler 1. Krüger P, et al. Eur Respir J 2014;44 Suppl 58:4635; 2. Malmberg LP, et al. J Aerosol Med Pulm Drug Deliv 2014;27:329-4

#### Higher resistance translates to a lower inspiratory flow through the inhaler


Inspiratory resistance of marketed dry powder inhalers and respective inspiratory flows studied at a pre-set equal pressure drop rate of  $4 kPa^{1,2}$ 



\*Easyhaler M (Monotherapy) is a high resistance inhaler and Easyhaler C (Combination) is a medium-to-high resistance inhaler 1. Krüger P, et al. Eur Respir J 2014;44 Suppl 58:4635; 2. Malmberg LP, et al. J Aerosol Med Pulm Drug Deliv 2014;27:329-40

# Easyhaler inhalers enable optimal turbulent air flow across all patient groups<sup>1,2</sup>

Mean (SD) maximum pressure change, as a measure of turbulent air flow, generated through dry powder inhalers (N=98 [16 children, 53 adults, 29 patients with COPD])<sup>1</sup>




COPD: chronic obstructive pulmonary disease; SD: standard deviation; \*data provided for the Easyhaler M (Monotherapy) 1. Azouz W, et al. J Aerosol Med Pulm Drug Deliv 2015;28:35-42; 2. Malmberg LP, et al. J Aerosol Med Pulm Drug Deliv 2014;27:329-40



# With Easyhaler optimal drug delivery can be achieved even with low patient inhalation flow

Inhaler resistance,<sup>1</sup> and optimal PIF for adequate drug delivery<sup>2</sup> of marketed dry powder inhalers



PHARMA


Optimal PIF level indicates that at this level, as well as any higher level, the patient receives the labelled dose.<sup>2</sup>

PIF of 30 L/min is reported as optimal for the Easyhaler.<sup>2,3</sup>

PIF: peak inspiratory flow; \*data provided for the Easyhaler M (Monotherapy); 1. Krüger P, et al. Eur Respir J 2014;44 Suppl 58:4635; 2. Ghosh S, et al. J Aerosol Med Pulm Drug Deliv 2017;30:381-7; 3. Haidl P, et al. Respir Med 2016;118:65-75

# Almost all asthma and COPD patients achieve a PIF of 30 L/min or higher<sup>1,2</sup>

PIF rates (L/min) for Easyhaler Monotherapy<sup>1</sup> and Combination<sup>2</sup> therapy inhalers in patients with asthma or COPD<sup>1,2</sup> (<sup>1</sup>N=93 patients with COPD; <sup>2</sup>N=181 patients [137 with asthma, 44 with COPD])



The vast majority of asthma and COPD patients, of varying age and disease severity, achieve a PIF of 30 L/min or higher with both Easyhaler


Monotherapy and Combination therapy inhalers.<sup>1,2</sup>

PIF: peak inspiratory flow; COPD: chronic obstructive pulmonary disease

1. Malmberg LP, et al. Int J Chron Obstruct Pulmon Dis 2010;5:257-62; 2. Malmberg LP, et al. J Aerosol Med Pulm Drug Deliv 2014;27:329-40

# Almost all patients achieve a PIF of 30 L/min or higher with an Easyhaler Combination therapy inhaler<sup>1</sup>

Individual PIF rates (L/min) for the Easyhaler Combination therapy inhaler<sup>1</sup> (N=181 patients [137 with asthma, including 52 children, and 44 with COPD])



#### Easyhaler Combination

PHARMA


All asthmatic patients and the vast majority patients with COPD, across a range of ages (6-82 years) and disease severities, are able to achieve a PIF rate of 30 L/min or higher with an Easyhaler Combination therapy inhaler.

In this study, Easyhaler PIF rates ranged from 35.4 to 101.4 L/min in asthmatic patients and from 27.0 to 83.7 L/min in patients with COPD.<sup>1</sup>

PIF: peak inspiratory flow; COPD: chronic obstructive pulmonary disease; EH: Easyhaler 1. Malmberg LP, et al. J Aerosol Med Pulm Drug Deliv 2014;27:329-40

#### The Easyhaler provides accurate and consistent dosing across patient inhalation flows

In vitro dose delivery from the Easyhaler Combination inhaler at three different peak inspiratory flows (each data point represents a single dose actuation)



Formoterol


The Easyhaler produces consistent dose delivery irrespective of a patient's inhalation flow.

Even at low patient inhalation flows, turbulent air flow generated within the inhaler is enough to sufficiently break up drug particles from their carrier.

\*10<sup>th</sup>/50<sup>th</sup>/90<sup>th</sup> percentile: peak inspiratory flows achieved by 90%, 50% and 10% of a patient population. These are indicative of high, medium and low inspiratory flows, respectively. Haikarainen J, et al. Pulm Ther 2017;3:125-38

# The Easyhaler provides consistent lung deposition irrespective of patient inhalation flows

Mean drug concentrations (SE) in plasma after two inhalations from the Easyhaler Combination inhaler at three different PIFs (N=16 healthy volunteers)




SE: standard error; PIF: peak inspiratory flow; \*PIF achieved by 90% of a patient population Malmberg LP, et al. J Aerosol Med Pulm Drug Deliv 2014;27:329-40

The area under the curve is representative of lung deposition.

In this study, both drugs were administered with concomitant oral charcoal to prevent absorption via the gastrointestinal tract, and to assess absorption via the lungs only.

# Fine particle doses with the Easyhaler are independent of patient inhalation flows

Delivered fine particle dose in vitro using the  $10^{th}$ ,  $50^{th}$  and  $90^{th}$  percentile of the PIFs



In this study, the delivered fine particle dose with Easyhaler was independent of patient inhalation flow, and comparable to that observed with Turbuhaler.

FPD: fine particle dose; PIF: peak inspiratory flow Malmberg LP, et al. J Aerosol Med Pulm Drug Deliv 2014;27:329-40

#### Summary



- Turbulent air flow generated inside a dry powder inhaler during a patient's inhalation is the main driver for efficient de-aggregation of the drug dose, and dose delivery<sup>1</sup>
- The Easyhaler is a high or medium-to-high resistance inhaler generating highly turbulent air flow<sup>2</sup>
- With both Easyhaler inhalers (M and C), the vast majority of patients can achieve a PIF greater than 30 L/min,<sup>3,4</sup> which is considered as optimal for the Easyhaler<sup>5</sup>
- Dose delivery with the Easyhaler is accurate and consistent across a wide range of patient inhalation flows, with efficient and consistent lung deposition and fine particle dose delivery irrespective of patient inhalation flows<sup>4,6</sup>

PIF: peak inspiratory flow; 1. Azouz W and Chrystyn H. Prim Care Respir J 2012;21:208-13; 2. Azouz W, et al. J Aerosol Med Pulm Drug Deliv 2015;28:35-42; 3. Malmberg LP, et al. Int J Chron Obstruct Pulmon Dis 2010;5:257-62; 4. Malmberg LP, et al. J Aerosol Med Pulm Drug Deliv 2014;27:329-40; 5. Ghosh S, et al. J Aerosol Med Pulm Drug Deliv 2017;30:381-7; 6. Haikarainen J, et al. Pulm Ther 2017;3:125-38





Fine particle

A particle with a diameter of < 5µm

The fastest flow recorded during an inspiratory cycle

Peak inspiratory flow

Resistance

Opposition to air flow

Turbulent air flow (sometimes referred to as *turbulent energy*) The flow of air, in which molecules move in a random, non-ordered manner; the opposite of laminar flow, which is smooth, uninterrupted air flow